ORIGINAL ARTICLE

Brain and Behavior

White matter microstructure alterations in frontotemporal dementia: Phenotype-associated signatures and single-subject interpretation

Mary Clare McKenna^{1,†} | Marlene Tahedl^{1,†} | Aizuri Murad¹ | Jasmin Lope¹ | Orla Hardiman¹ | Siobhan Hutchinson² | Peter Bede^{1,2}

¹ Computational Neuroimaging Group, Trinity College Dublin, Dublin, Ireland

² Department of Neurology, St James's Hospital, Dublin, Ireland

Correspondence

Peter Bede, Computational Neuroimaging Group, Room 5.43, Trinity Biomedical Sciences Institute, 152–160 Pearse Street, Trinity College Dublin, Dublin 2, Ireland. Email: bedep@tcd.ie

[†]Mary Clare McKenna and Marlene Tahedl are joint first authors.

Funding information

Health Research Board, Grant/Award Number: HRB EIA-2017-019; Spastic Paraplegia Foundation; EU Joint Programme – Neurodegenerative Disease Research; Andrew Lydon scholarship; Irish Institute of Clinical Neuroscience; Iris O'Brien Foundation

Abstract

Background: Frontotemporal dementias (FTD) include a genetically heterogeneous group of conditions with distinctive molecular, radiological and clinical features. The majority of radiology studies in FTD compare FTD subgroups to healthy controls to describe phenotype- or genotype-associated imaging signatures. While the characterization of group-specific imaging traits is academically important, the priority of clinical imaging is the meaningful interpretation of individual datasets.

Methods: To demonstrate the feasibility of single-subject magnetic resonance imaging (MRI) interpretation, we have evaluated the white matter profile of 60 patients across the clinical spectrum of FTD. A *z*-score-based approach was implemented, where the diffusivity metrics of individual patients were appraised with reference to demographically matched healthy controls. Fifty white matter tracts were systematically evaluated in each subject with reference to normative data.

Results: The *z*-score-based approach successfully detected white matter pathology in single subjects, and group-level inferences were analogous to the outputs of standard track-based spatial statistics.

Conclusions: Our findings suggest that it is possible to meaningfully evaluate the diffusion profile of single FTD patients if large normative datasets are available. In contrast to the visual review of FLAIR and T2-weighted images, computational imaging offers objective, quantitative insights into white matter integrity changes even at single-subject level.

KEYWORDS

amyotrophic lateral sclerosis, biomarker, frontotemporal dementia, MRI, neuroimaging

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC

Open Access

1 | INTRODUCTION

White matter (WM) changes in frontotemporal dementia (FTD) have been extensively studied, and both clinical subtypes (Agosta et al., 2012; Borroni et al., 2007; Lam et al., 2014; Mahoney et al., 2014; Schwindt et al., 2013; Whitwell et al., 2010) and genotypes (Jiskoot et al., 2018, 2019; Rohrer et al., 2010) have been linked to relatively specific WM signatures. The most commonly utilized WM technique is diffusion tensor imaging (DTI), but a variety of non-Gaussian techniques such as diffusion kurtosis imaging (DKI) and neurite orientation dispersion and density imaging (NODDI) have also been successfully utilized (Wen et al., 2019). WM alterations in FTD can already be detected in the presymptomatic phase of the disease, and WM alterations are relatively marked by the time the diagnosis can be established (Wen et al., 2019). WM changes can also be readily tracked longitudinally across multiple timepoints to appraise the rate of progression and patterns of anatomical propagation. A shortcoming of descriptive imaging studies in FTD is that often only group-level inferences are presented, that is, shared patterns of WM disease burden in specific phenotypes or genotypes. The demands of clinical imaging differ significantly from the deliverables of academic radiology (Bede et al., 2018). The emphasis in the clinical setting is the accurate categorization of a suspected patient into a diagnostic subgroup, the evaluation of an asymptomatic mutation carrier with regard to presymptomatic disease burden, or the follow-up of a specific patient with an established diagnosis to verify if further pathology has been accrued (Chipika et al., 2019; Chipika, Siah, et al., 2020). The gap between group-level imaging and single-subject imaging is considerable in terms of practical utility, methodological challenges and academic relevance (Verstraete et al., 2015). While patterns of gray matter atrophy can be assessed in a variety of ways, the interpretation of single-subject WM profiles is particularly challenging. The visual inspection of FLAIR and T2-wighted images offers limited information, and the visual review of DTI data only permits the appreciation of movement, susceptibility or eddy-current related artefacts. In current clinical practice, the primary role of magnetic resonance imaging (MRI) is the exclusion of neoplastic, paraneoplastic, inflammatory and structural mimics rather than the confirmation of FTD-associated changes. Existing frameworks for single-subject categorization rely on various machine learning algorithms to classify single individuals into groups. A variety of supervised and unsupervised methods have been previously implemented across the spectrum of ALS-FTD. Models such as support vector machines, decision trees, neural networks and discriminant function analyses have been applied to imaging datasets with varying accuracy (Bede et al., 2017; Bede, Murad, et al., 2021; Cajanus et al., 2018; Chagué et al., 2020; Davatzikos et al., 2008; Donnelly-Kehoe et al., 2019; Egger et al., 2020; Feis et al., 2018, 2020; Feis, Bouts, de Vos, et al., 2019; Feis, Bouts, Panman, et al., 2019; Grollemund et al., 2019; Klöppel et al., 2015; Koikkalainen et al., 2016; Manera et al., 2021; Schuster et al., 2016, 2017; Tong et al., 2017; Torso et al., 2020; Vernooij et al., 2018; Young et al., 2018). A common application of these approaches is the categorization of patients into FTD versus AD diagnostic groups. (Bouts et al., 2018; Bron et al., 2017; Canu et al., 2017; Frings et al.,

2014; Hu et al., 2020; Kim et al., 2019; Ma et al., 2020; Möller et al., 2016; Wang et al., 2016; Yu et al., 2021). A key barrier to the development of successful machine learning algorithms in neurodegenerative conditions is the scarcity of uniformly acquired training data, especially in low-incidence phenotypes such as ALS-FTD, PLS-FTD, and postpolio syndrome (Aho-Ozhan et al., 2016; Finegan et al., 2019, 2021; Li Hi Shing, Lope, Chipika, et al., 2021; Li Hi Shing, Lope, McKenna, et al., 2021; Lule et al., 2010; McKenna, Corcia, et al., 2021; Pioro et al., 2020; Trojsi et al., 2015, 2019; Trojsi, Di Nardo, Siciliano, et al., 2020). Accordingly, the objective of this study is to pilot an alternative quantitative WM rating framework for single-subject diffusion data interpretation based on tractwise *z*-scoring of diffusivity metrics with reference to demographically matched controls.

2 | METHODS

2.1 | Participants

A total of 160 subjects were enrolled in this study. Sixty patients were included from across the clinical spectrum of FTD: seven patients with behavioral variant FTD (bvFTD, four males, mean age = 60.71 ± 3.30 years), nine patients with nonfluent variant primary progressive aphasia (nfvPPA, five males, mean age = 62.22 ± 3.03 years), three patients with semantic-variant PPA (svPPA, two males, mean age = $61.67 \pm$ 6.43 years), 21 patients with ALS-FTD carrying hexanucleotide repeat expansions in C9orf72 (ALSFTD-C9+, 13 males, mean age = $58.95 \pm$ 9.95 years) and 20 ALS-FTD patients who tested negative for C9orf72 (ALSFTD-C9NEG, 13 males, mean age = 60.65 ± 8.73 years). The imaging profiles of patients were interpreted based on radiological data from 100 healthy controls (HC, 50 males, mean age = 58.95 ± 9.95 years). Patients were diagnosed according to the Rascovsky and El Escorial criteria. The z-scoring strategy implemented in this study relies on the rating of single subjects' data with respect to a demographically matched control population. Accordingly, control selection for normative data generation was defined based on age to ensure age matching between each male/female patient and the corresponding male/female control group. Two-sample t-tests were performed to verify successful age matching. Sex matching was ensured by contrasting each male/female patient only to male/female controls. Given the available number of total controls, only one male and one female control group were defined, each of size n = 50. Relevant demographic data are presented in Table 1. Methods for ascertaining GGGGCC hexanucleotide repeat expansion in C9orf72 by repeat-primed PCR have been described previously (Chipika, Christidi, et al., 2020; Kenna et al., 2013), and expansions longer than 30 hexanucleotide repeats were considered pathological.

2.2 Data acquisition

A spin-echo echo planar imaging (SE-EPI) pulse sequence with a 32direction Stejskal-Tanner diffusion encoding scheme was used to **Brain and Behavior**

TABLE 1 Demographic data

	Male		Female		
Patient group	Mean age (SD) (years),	<i>t</i> -Score from two-sample <i>t</i> -test	Mean age (SD) (years),	<i>t</i> -Score from two-sample <i>t</i> -test	
	sample size (n)	(DOF), <i>p</i> -value (HC vs. patients)	sample size (n)	(DOF), <i>p</i> -value (HC vs. patients)	
ALSFTD-C9+	55.92 (8.11),	t(61) = 1.73,	58.50 (9.61),	t(56) = -0.42,	
	n = 13	p = .09	n = 8	p = 0.68	
ALSFTD-C9-	62.00 (9.11),	t(61) = -0.35,	58.14 (7.98),	t(55) = -0.31,	
	n = 13	p = .73	n = 7	p = .76	
bvFTD	59.25 (3.50),	t(52) = 0.35,	62.67 (2.98),	t(51) = -0.99,	
	n = 4	p = .73	n = 3	p = .33	
nfvPPA	63.60 (2.97),	t(53) = -0.60,	60.50 (3.42),	t(52) = -0.71,	
	n = 5	p = .55	n = 4	p = .48	
svPPA	58.00 (1.41),	t(50) = 0.43,	69.00 (0.00),	t(49) = -1.21,	
	n = 2	p = .67	n = 1	p = .23	
HC	60.96 (9.68), n = 50		56.94 (9.91), n = 50		

Note: ALSFTDC9-: ALS-FTD patients without *C9orf72* hexanucleotide expansions, ALSFTDC9+: ALS-FTD patients with *C9orf72* hexanucleotide expansions Abbreviations: bvFTD, behavioral variant FTD; DOF, degrees of freedom; HC, healthy control; nfvPPA, nonfluent variant primary progressive aphasia; svPPA, semantic variant primary progressive aphasia.

acquire DTI data on a 3 Tesla Philips Achieva MR platform. The key parameters included TR/TE = 7639/59 ms, b-values = 0.1100 s/mm², $FOV = 245 \times 245 \times 150$ mm, spatial resolution = 2.5 mm³, 60 axial slices with no interslice gaps, SENSE factor = 2.5, dynamic stabilization and spectral presaturation with inversion recovery (SPIR) fat suppression. For the visual assessment of co-morbid WM pathology, FLAIR images were also reviewed of each participant. FLAIR data were acquired in the axial orientation using an inversion recovery turbo spin echo (IR-TSE) seguence: FOV = $230 \times 183 \times 150$ mm, spatial resolution = $0.65 \times 0.87 \times 4$ mm, TR/TE = 11000/125 ms, $TI = 2800 \text{ ms}, 120^{\circ}$ refocusing pulse, with flow compensation and motion smoothing and a saturation slab covering the neck region. T1weighted (T1w) images were acquired with a 3D inversion recovery prepared spoiled gradient recalled echo (IR-SPGR) sequence with a field-of-view (FOV) of $256 \times 256 \times 160$ mm, spatial resolution of 1 mm^3 , TR/TE = 8.5/3.9 ms, TI = 1060 ms, flip angle = 8°, SENSE factor = 1.5.

2.3 Diffusion-weighted data processing

Diffusion-weighted (DW) data were preprocessed within *MRtrix3*, including noise removal and removal of Gibb's Ringing Artifacts. The *topup-eddy* algorithm was utilized for corrections for eddy-induced distortions and subject movements as implemented in FSL. Bias correction was performed with the ANTs1.9 N4 method. Diffusion tensors were fitted within *MRtrix3*, and maps of fractional anisotropy (FA) and radial diffusivity (RD) were generated. Anatomical images were preprocessed using FMRIB's FSL6.0's *fsl-anat* algorithm, including brain-extraction and biasfield-corrections.

2.4 | Tract segmentation

As the main objective of the study was the detection of WM microstructure integrity changes in individual patients, our analyses were restricted to regions of FA reductions and foci of increased RD as these diffusivity shifts indicate pathologic processes. Tract-wise probabilities of presumed pathology in individual subjects were estimated based on reference normative data. First, each patient's and control's DW data were segmented into 50 WM tracts using a neuralnetwork-based algorithm, TractSeg, which, as opposed to atlas-based approaches, does not assume a common anatomy between subjects and relies on individual WM fiber bundles anatomy. Peaks of the spherical harmonic function were extracted at each voxel to inform Tract-Seg, which were calculated from fitting voxelwise constrained spherical deconvolution (CSD). CSD is an alternative to the tensor model to perform tractography, which has been shown to outperform the tensor model in regions of crossing fibers, among others. Response functions were estimated using the dhollander method as implemented in MRtrix3 from which fiber orientation distribution function (fODF) could be calculated. Given that DW shells were acquired (b = 1000 and b = 0), a multishell approach could be implemented. Resulting fODFs were normalized according to (Raffelt et al., 2017); spherical harmonic peaks were retrieved from the normalized measures, which then served as input values into TractSeg.

2.5 | z-Score-based tract integrity evaluation

The concept behind the z-scored-based strategy is the ascertainment of affected fiber bundles in individual patients. WM tracts were rated **Brain and Behavior**

in individual patients with reference to age- or sex-matched HCs. Only tracts exhibiting significant FA reductions and increased RD were considered "affected." First, subject-specific FA and RD maps were created for the segmented tracts by inputting each subjects' individual FA/RD map into *TractSeg* and averaging the estimated values across each tract. Normative data from HCs were *z*-scored, and patient data were normalized with respect to the relevant control group. Single patients' tract profiles were then contrasted to normative data using nonparametric statistics. First, the number of HCs exhibiting lower FA and higher RD than the observed value in the patient was determined for each patient and each tract. This value was then divided by the number of HCs (i.e., 50 both for males and females) to obtain *p*-values. Given that two tests were run (decreased FA/increased RD), tracts with p < .025 were considered significantly different.

Finally, group-level statistics were also derived from the *z*-scorebased strategy to aid cross-validation against the standard approach. We tested which tracts were preferentially affected across the entire patient group. To quantify this probability, probability distributions were first created reflecting the number of false positives across the patient group (i.e., *p*-values of < .025 provided a random event). This was modeled as a binomial process:

$$X \sim B(n, p), \tag{1}$$

where X is the random variable (a scalar), n is the number of correctly segmented tracts in the control distribution and p is the probability of assigning significance to a tract's p-value (in our case 0.025). This process was repeated 100,000 times to provide a dense probability distribution. p-Values were then derived for each tract by counting how many values in the null distribution exceeded the sum of significant observations across the patient group and dividing that count by the number of iterations. To match the threshold used in the validation arm of the study, the most affected tracts were identified using a relatively stringent alpha-threshold of p < .01.

2.6 Cross-validation by standard tract-based statistics

To validate the *z*-score-based approach, the group-level outputs were compared to those of an established analysis pipeline, FMRIB FSL's tract-based spatial statistics (TBSS). The voxelwise diffusivity profile of the five FTD groups was contrasted to controls. In accordance with FSL's TBSS recommendations, processing included outliner removal, nonlinear registration to the FMRIB58FA template and application of that transformation to align all subjects' FA/RD images to the MNI152 1 mm standard space. Voxelwise group-comparisons were computed using FSL's *randomise* algorithm, a nonparametric permutation testing scheme, with 2D-optimized threshold-free cluster enhancement (TFCE) to control for the family-wise error rate (FWER). To highlight the most pertinent WM changes, a stringent alpha-threshold of $p_{FWER} < .01$ was applied.

3 | RESULTS

oen Acces

3.1 Demographics

Two-sample *t*-tests were run between each male/female patient group versus the male/female control groups to confirm age matching. No statistical difference was found between any of the patient and control groups suggesting appropriate age matching. Relevant descriptive and inferential statistics are provided in Table 1.

3.2 | z-Score-based subject-level inferences

The z-score-based strategy has successfully captured relevant WM pathology in individual subjects in each of the 60 FTD patients. A dual-output scheme was utilized. Affected WM tracts can be depicted in 3D, and a text file was also generated listing the affected tract with the relevant z- and p-values. To showcase the potential utility of single-subject WM profile interpretation, we provide representative individual examples from the five patient groups (Figure 1). As descried in Section 2, the z-score-based strategy also permits the description of group-level findings. An overview of affected tracts at a group level is provided in Tables 2-3 for each FTD cohort. More tracts were detected exhibiting increased RD than tracts with FA reductions, suggesting that RD may be more sensitive to capture relevant WM degeneration. Our approach detected left-hemisphere dominant changes in language variant phenotypes (nfvPPA and svPPA) compared to the relatively symmetric pathology in bvFTD and ALS-FTD groups. Relative sparing of posterior WM bundles was observed across the entire spectrum of subgroups.

3.3 | Validation

For validation purposes, standard TBSS analyses were performed to contrast each of the five FTD groups to HCs. Widespread, multilobar FA reductions were detected in both ALS-FTD groups irrespective of C9orf72 status (Figure 2). Anterior frontal and left hemisphere predominant FA reductions were identified in the nfvPPA group. At p < .01, no significant FA reductions were identified in the svPPA and bvFTD groups. At the same statistical threshold, areas of increased RD were detected in each FTD group: orbitofrontal and forceps minor predominant changes in bvFTD, left superior temporal and insular WM alterations in svPPA and extensive multilobar WM degeneration in nfvPPA, ALS-FTD-C9+ and ALS-FTD-C9-. (Figure 3). While RD was more sensitive in detecting WM pathology in bvFTD and svPPA, FA was more sensitive in detecting cerebellar changes in the two ALS-FTD groups compared to RD. Occipital involvement was relatively limited in the nfvPPA group.

	Affected tract	<i>z</i> -score	<i>p</i> -value
. bvFTD	Anterior thalamic radiation Rt Corpus callosum: Rostrum Corpus callosum: Genu Fronto-pontine tract Rt Inferior occipito-frontal fasc. Rt Thalamo-premotor Rt Striato-premotor Rt	1.262 1.253 2.869 1.001 1.286 0.846 1.736 0.986	0.020 0.020 0.000 0.000 0.000 0.020 0.020 0.020
FTD-C9.	Corticospinal tract Lt Corticospinal tract Rt Sup thalamic radiation Lt Sup thalamic radiation Rt	0.884 0.824 0.674 0.694	0.000 0.000 0.000 0.020
ALSI	Arcuate fascicle Rt Corpus callosum: Ant.body Corpus callosum: Post.body	0.883 1.070 1.635	0.020 0.000 0.020
PA ALSFTD-C9+ /	Corpus calosum. Postbody Corticospinal tract Lt Corticospinal tract Rt Inferior cerebellar peduncle Lt Inferior longitudinal fascicle Rt Middle cerebellar peduncle Optic radiation Rt Parieto-occipital pontine Lt Parieto-occipital pontine Rt Superior cerebellar peduncle Rt Superior longitudinal fasc. III Rt	1.035 1.929 1.757 1.456 2.310 1.305 2.221 2.069 1.254 0.946 1.973 1.216 1.476	0.020 0.000 0.020 0.000 0.000 0.000 0.000 0.000 0.020 0.000 0.000 0.000 0.000
svPF	Thalamo-occipital Rt -{Uncinate fascicle Lt	2.082 1.614	0.000
nfvPPA	Arcuate fascicle Lt Anterior thalamic radiation Lt Corpus callosum: Genu Corpus callosum: Rostral body Superior longitudinal fasc. II Lt Superior longitudinal fasc. III Lt Uncinate fascicle Lt Thalamo-premotor Lt Striato-premotor Lt	3.500 1.537 2.977 1.762 1.022 1.231 0.881 2.372 1.880	0.000 0.020 0.020 0.020 0.020 0.020 0.000 0.000 0.000 0.020

FIGURE 1 White matter alterations in individual subjects based on single diffusion tensor imaging (DTI) datasets and normative data. Illustrative outputs from single patients with behavioral variant FTD (bvFTD), ALS-FTD patients without *C9orf72* hexanucleotide expansions (ALSFTD-C9-), ALS-FTD patients with *C9orf72* hexanucleotide expansions (ALSFTD-C9+), semantic variant primary progressive aphasia (svPPA) and nonfluent variant primary progressive aphasia (nfvPPA)

4 DISCUSSION

We have successfully captured phenotype-specific WM alterations in individual FTD patients using a z-scored-based strategy. The grouplevel findings inferred from the trialed WM rating scheme were consistent with the outputs of established pipelines. Our results indicate that it is feasible to interpret single DTI datasets if large reference datasets are available with uniform scanning parameters. In a clinical setting, gray matter atrophy can often be qualitatively appreciated in patients with FTD (Hardiman et al., 2016). In contrast, WM changes cannot be meaningfully commented upon beyond the exclusion of demyelination, inflammatory or vascular changes. WM changes are typically reviewed visually on T2w, FLAIR and DWI to make sure the suspected diagnosis is not confounded by coexisting vascular, inflammatory or neoplastic, or paraneoplastic pathology. In established cases of FTD, FLAIR and T2w images often look relatively FA reductions

TABLE 2 Affected white matter tracts in ALS-FTD at group level

ALS-FTD with GGGGCC hexanucleotide repeat expansions in C9orf72 (C9orf72+)

MCKENNA ET AL.

Tract name	p _{FWER}	Tract name	p _{FWER}	Tract name	$p_{\rm FWER}$
Arcuate fascicle right	.0011	Arcuate fascicle left	.0001	Optic radiation right	<.0001
Corpus callosum: rostrum	.0096	Arcuate fascicle right	<.0001	Parieto-occipital pontine left	<.0001
Corpus callosum: genu	.0009	Corpus callosum: rostrum	<.0001	Parieto-occipital pontine left	.0008
Corpus callosum: anterior midbody	.0001	Corpus callosum: genu	.0010	Superior cerebellar peduncle right	.0008
Corpus callosum: posterior midbody	<.0001	Corpus callosum: rostral body	.0029	Superior longitudinal fascicle I left	<.0001
Corpus callosum: isthmus	.0011	Corpus callosum: anterior midbody	<.0001	Superior longitudinal fascicle I right	.0001
Corpus callosum: splenium	<.0001	Corpus callosum: posterior midbody	.0001	Superior longitudinal fascicle II left	.0012
Cingulum left	.0012	Corpus callosum: isthmus	.0011	Superior longitudinal fascicle II right	.0009
Cingulum right	.0013	Corpus callosum: splenium	.0010	Superior longitudinal fascicle III left	.0084
Corticospinal tract left	.0073	Cingulum left	<.0001	Superior longitudinal fascicle III right	.0001
Corticospinal tract right	<.0001	Cingulum right	.0013	Superior thalamic radiation left	<.0001
Fronto-pontine tract right	.0082	Corticospinal tract left	<.0001	Superior thalamic radiation right	<.0001
Optic radiation left	.0008	Corticospinal tract right	<.0001	Uncinate fascicle left	<.0001
Parieto-occipital pontine right	.0095	Fronto-pontine tract left	.0085	Uncinate fascicle right	.0004
Superior longitudinal fascicle I left	.0001	Fronto-pontine tract right	.0082	Thalamo-parietal right	.0001
Superior longitudinal fascicle I right	<.0001	Inferior cerebellar peduncle left	.0001	Thalamo-occipital left	<.0001
Superior longitudinal fascicle II left	.0010	Inferior cerebellar peduncle right	.0053	Thalamo-occipital right	<.0001
Superior longitudinal fascicle II right	.0007	Inferior occipito-frontal fascicle left	.0001	Striato-fronto-orbital right	<.0001
Superior longitudinal fascicle III right	<.0001	Inferior occipito-frontal fascicle right	<.0001	Right	
Superior thalamic radiation right	.0005	Inferior longitudinal fascicle left	<.0001		
Thalamo-occipital left	.0009	Inferior longitudinal fascicle right	<.0001		
Thalamo-occipital left Striato-fronto-orbital right	.0009 .0095	Inferior longitudinal fascicle right Optic radiation left	<.0001 <.0001		
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle	.0009 .0095 otide repe	Inferior longitudinal fascicle right Optic radiation left at expansions in <i>C9orf72</i> (C9orf72-)	<.0001 <.0001		
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions	.0009 .0095 otide repe	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD	<.0001 <.0001	Increased RD (continued)	
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name	.0009 .0095 otide repe	Inferior longitudinal fascicle right Optic radiation left at expansions in <i>C9orf72</i> (C9orf72-) Increased RD Tract name	<.0001 <.0001	Increased RD (continued) Tract name	<i>p</i> _{FWER}
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left	.0009 .0095 otide repea pewer .0097	Inferior longitudinal fascicle right Optic radiation left at expansions in <i>C9orf72</i> (C9orf72-) Increased RD Tract name Arcuate fascicle left	<.0001 <.0001 <i>p</i> _{FWER} .0001	Increased RD (continued) Tract name Parieto-occipital pontine right	р _{FWER} .0055
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu	.0009 .0095 otide repea PFWER .0097 .0007	Inferior longitudinal fascicle right Optic radiation left at expansions in <i>C9orf72</i> (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right	<.0001 <.0001 <i>P</i> FWER .0001 .0009	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left	р _{FWER} .0055 .0006
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium	.0009 .0095 otide repea PFWER .0097 .0007 .0005	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum	<.0001 <.0001 P FWER .0001 .0009 <.0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right	р _{FWER} .0055 .0006 .0059
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left	.0009 .0095 otide repea .0097 .0007 .0005 .0009	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: genu	<.0001 <.0001 <i>P</i> _{FWER} .0001 .0009 <.0001 <.0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right Superior longitudinal fascicle I left	P FWER .0055 .0006 .0059 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right	.0009 .0095 otide repea PFWER .0097 .0007 .0005 .0009 .0009	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: genu Corpus callosum: rostral body	<.0001 <.0001 P FWER .0001 .0009 <.0001 <.0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right Superior longitudinal fascicle I left Superior longitudinal fascicle I right	р _{FWER} .0055 .0006 .0059 <.0001 .0007
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right	.0009 .0095 otide repea PFWER .0097 .0007 .0007 .0005 .0009 .0002 .0002	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: genu Corpus callosum: rostral body Corpus callosum: isthmus	<.0001 <.0001 P FWER .0001 .0009 <.0001 <.0001 .0013 <.0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right Superior longitudinal fascicle I left Superior longitudinal fascicle I left	Р _{FWER} .0055 .0006 .0059 <.0001 .0007 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right Inferior occipito-frontal fascicle right Middle cerebellar peduncle	.0009 .0095 otide repea PFWER .0097 .0007 .0005 .0009 .0009 .0002 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: rostral body Corpus callosum: isthmus Corpus callosum: splenium	<.0001 <.0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior longitudinal fascicle I left Superior longitudinal fascicle II left Superior longitudinal fascicle II left Superior longitudinal fascicle II left	р _{FWER} .0055 .0006 .0059 <.0001 .0007 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right Inferior occipito-frontal fascicle right Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide reper PFWER .0097 .0007 .0007 .0009 .0009 .0008 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: rostral body Corpus callosum: isthmus Corpus callosum: splenium Corpus callosum: splenium Conpus callosum: splenium	<.0001 <.0001 P FWER .0001 .0009 <.0001 <.0001 .0013 .0080 .0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior longitudinal fascicle I left Superior longitudinal fascicle II left Superior longitudinal fascicle III left Superior longitudinal fascicle III left Superior longitudinal fascicle III left	Реже .0055 .0006 .0059 <.0001 .0007 <.0001 .0060 .0067
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right Inferior occipito-frontal fascicle right Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide repea PFWER .0097 .0007 .0005 .0009 .0002 .0008 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: rostrum Corpus callosum: rostral body Corpus callosum: isthmus Corpus callosum: splenium Corpus callosum: splenium Cingulum left Cingulum right	<.0001 <.0001 P FWER .0001 .0001 <.0001 .0013 .0080 .0001 .0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior longitudinal fascicle I left Superior longitudinal fascicle I left Superior longitudinal fascicle II left Superior longitudinal fascicle III left Superior longitudinal fascicle III right Superior longitudinal fascicle III right	Р _{FWER} .0055 .0006 .0059 <.0001 .0007 <.0001 .0060 .0067 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right Inferior occipito-frontal fascicle right Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide repea PFWER .0097 .0007 .0007 .0009 .0009 .0002 .0068 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle left Corpus callosum: rostrum Corpus callosum: rostrum Corpus callosum: splenium Corpus callosum: splenium Corpus callosum: splenium Conpus callosum: splenium Corpus callosum COPUS COPU	<.0001 <.0001 PFWER .0001 .0009 <.0001 .0013 <.0001 .0001 .0001 .0001 .0070 <.0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right Superior longitudinal fascicle I left Superior longitudinal fascicle I lift Superior longitudinal fascicle II left Superior longitudinal fascicle III left Superior longitudinal fascicle III left Superior longitudinal fascicle III right Superior longitudinal fascicle III right Superior longitudinal fascicle III right Superior thalamic radiation left	Режек .0055 .0006 .0059 <.0001 .0007 <.0001 .0067 <.0001 .0067 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Corpus callosum: splenium Corpus callosum: splenium Corpus callosum: splenium Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide repea PFWER .0097 .0007 .0005 .0009 .0002 .0008 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: genu Corpus callosum: genu Corpus callosum: strhaus Corpus callosum: strhaus Corpus callosum: splenium Corpus callosum: splenium Corpus callosum: splenium Corpus callosum: splenium Corpus callosum: splenium Corpus callosum: splenium Corpus callosum: splenium	<.0001 <.0001 PFWER .0001 .0009 <.0001 .0013 <.0001 .0080 .0001 .0070 <.0001 .0070 <.0001	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior longitudinal fascicle I left Superior longitudinal fascicle I left Superior longitudinal fascicle II left Superior longitudinal fascicle III right Superior longitudinal fascicle III right Superior thalamic radiation left Uncinate fascicle left	PFWER .0055 .0006 .0059 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide repea PFWER .0097 .0007 .0007 .0009 .0009 .0002 .0068 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: rostrum Corpus callosum: splenium Corpus callosum Corpus callosum: splenium Corpus callosum Corpus callosum Co	<.0001 <.0001 PFWER .0001 .0009 <.0001 .0013 .0013 .0001 .0001 .0001 .0001 .0001 .0001 .0001 .0002	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right Superior longitudinal fascicle I left Superior longitudinal fascicle I left Superior longitudinal fascicle II left Superior longitudinal fascicle III right Superior longitudinal fascicle III right Superior thalamic radiation right Superior thalamic radiation right Uncinate fascicle left	PFWER .0055 .0006 .0059 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right Inferior occipito-frontal fascicle right Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide repea PFWER .0097 .0007 .0007 .0009 .0009 .0008 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left expansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: rostrum Corpus callosum: genu Corpus callosum: sthmus Corpus callosum: splenium Corpus callosum Corpus callosum: splenium Corpus callosum Corpus callosum: splenium Corpus callosum Corpus	<.0001 <.0001 PFWER .0001 .0009 <.0001 .0013 .0013 .0001 .0001 .0001 .0001 .0001 .0001 .0001 .0002 .0003 .0003	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right Superior longitudinal fascicle I left Superior longitudinal fascicle I left Superior longitudinal fascicle II left Superior longitudinal fascicle III left Superior longitudinal fascicle III right Superior thalamic radiation right Incinate fascicle left Uncinate fascicle right Thalamo-parietal left	PFWER .0055 .0006 .0059 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide repea PFWER .0097 .0007 .0005 .0009 .0002 .0068 .0068 .0072	Inferior longitudinal fascicle right Optic radiation left Arexpansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: rostrum Corpus callosum: rostral body Corpus callosum: splenium Corpus callosum Corpus callosum: splenium Corpus callosum Corpus callosum Co	<.0001 <.0001 PFWER .0001 .0009 <.0001 .0013 .0013 .0013 .0011 .0080 .0001 .0070 .0002 .0003 .0071 .0075	Increased RD (continued) Iract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior longitudinal fascicle I left Superior longitudinal fascicle I left Superior longitudinal fascicle I left Superior longitudinal fascicle II left Superior thalamic radiation left Superior thalamic radiation right Incinate fascicle left Thalamo-parietal left	PFWER .0055 .0006 .0059 <.0001
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Congulum left Corticospinal tract right Inferior occipito-frontal fascicle right Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide repea PFWER .0097 .0007 .0005 .0009 .0002 .0068 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left Optic radiation left Texpansions in C9orf72 (C9orf72-) Increased RD Tract name Arcuate fascicle left Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: rostrum Corpus callosum: splenium Corpus callosum Corpus callosum: splenium Corpus callosum	<.0001 <.0001 PFWER .0001 .0009 <.0001 .0013 .0013 .0013 .0001	Increased RD (continued) Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right Superior longitudinal fascicle I left Superior longitudinal fascicle I light Superior longitudinal fascicle II left Superior longitudinal fascicle III left	Режек .0055 .0006 .0007 .0001 .0007 .0001 .0060 .0067 .0001 .0047 .0001 .0047 .0001 .0064 .0004 .0069
Thalamo-occipital left Striato-fronto-orbital right ALS-FTD without GGGGCC hexanucle FA reductions Tract name Arcuate fascicle left Corpus callosum: genu Corpus callosum: splenium Cingulum left Corticospinal tract right Inferior occipito-frontal fascicle right Middle cerebellar peduncle Superior longitudinal fascicle III right	.0009 .0095 otide reper- PFWER .0097 .0007 .0007 .0009 .0009 .0008 .0068 .0068 .0068	Inferior longitudinal fascicle right Optic radiation left at expansions in C9orf72 (C9orf72-) at expansions in C9orf72 (C9orf72-) at cased RD Tract name Arcuate fascicle left Arcuate fascicle left Arcuate fascicle right Corpus callosum: rostrum Corpus callosum: rostrum Corpus callosum: splenium Corticospinal tract left Corticospinal tract right Inferior cerebellar peduncle left Inferior occipito-frontal fascicle right Middle cerebellar peduncle	<.0001 <.0001 PFWER .0001 .0009 <.0001 .0013 .0013 .0013 .0014 .0001 .0005	Increased RD (continued) Tract name Parieto-occipital pontine right Superior cerebellar peduncle left Superior cerebellar peduncle right Superior longitudinal fascicle I left Superior longitudinal fascicle I left Superior longitudinal fascicle II left Superior longitudinal fascicle III left Superior longitudinal fascicle III left Superior longitudinal fascicle III right Superior thalamic radiation right Incinate fascicle right Inalamo-parietal left Thalamo-occipital right Striato-fronto-orbital left Striato-premotor left	PFWER .0055 .0059 .0001 .0007 .0001 .0060 .0061 .0047 .0041 .0047 .0041 .0047 .0041 .0041 .0041 .0041 .0041 .0041 .0041 .0041 .0041 .0041 .0041 .0041 .0041 .0041

n Acc

Increased RD

Abbreviations: FA, fractional anisotropy; RD, radial diffusivity.

/II FN

TABLE 3 Affected white matter tracts in behavioral variant FTD (bvFTD), nonfluent variant primary progressive aphasia (nfvPPA) and semantic variant primary progressive aphasia (svPPA) at group level

Decreased FA		Increased RD		
Tract name	<i>p</i> _{FWER}	Tract name	p _{FWER}	
bvFTD				
Corpus callosum: genu	<.0001	Arcuate fascicle left	.0004	
		Corpus callosum: rostrum	<.0001	
		Corpus callosum: genu	<.0001	
		Corticospinal tract right	.0005	
		Fronto-pontine tract right	.0003	
		Inferior occipito-frontal fascicle right	.0006	
		Superior thalamic radiation left	.0002	
		Superior thalamic radiation right	.0006	
		Uncinate fascicle right	.0006	
		Thalamo-premotor right	.0006	
		Striato-fronto-orbital left	.0005	
		Striato-fronto-orbital right	.0005	
		Striato-premotor right	.0005	
nfvPPA				
Corpus callosum: genu	<.0001	Arcuate fascicle left	<.0001	
Cingulum left	.0014	Arcuate fascicle right	.0014	
Superior longitudinal fascicle I left	.0008	Anterior thalamic radiation left	.0005	
Superior longitudinal fascicle II left	.0006	Anterior thalamic radiation right	<.0001	
Thalamo-premotor left	.0059	Corpus callosum: rostrum	.0001	
		Corpus callosum: genu	<.0001	
		Corpus callosum: rostral body	.0018	
		Corpus callosum: post. midbody	.0007	
		Cingulum left	<.0001	
		Cingulum right	.0011	
		Fronto-pontine tract left	.0004	
		Fronto-pontine tract right	.0005	
		Inferior occipito-frontal fascicle left	<.0001	
		Inferior occipito-frontal fascicle right	<.0001	
		Inferior longitudinal fascicle right	.0011	
		Optic radiation left	<.0001	
		Optic radiation right	.0001	
		Superior longitudinal fascicle I left	<.0001	
		Superior longitudinal fascicle I right	.0001	
		Superior longitudinal fascicle II left	<.0001	
		Superior longitudinal fascicle II right	.0008	
		Superior longitudinal fascicle III left	<.0001	
		Superior longitudinal fascicle III right	.0012	
		Uncinate fascicle left	.0007	
		Thalamo-premotor left	.0002	
		Thalamo-parietal left	.0013	

(Continues)

^{8 of 15} WILEY Brain and Behavior

TABLE 3 (Continued)

Decreased FA		Increased RD		
Tract name	P _{FWER}	Tract name	PFWER	
		Thalamo-parietal right	.0001	
		Thalamo-occipital left	.0008	
		Thalamo-occipital right	.0001	
		Striato-fronto-orbital left	<.0001	
		Striato-fronto-orbital right	<.0001	
svPPA				
Inferior occipito-frontal fascicle left	.0018	Arcuate fascicle left	.0023	
Superior longitudinal fascicle III left	.0017	Arcuate fascicle right	.0018	
		Corpus callosum: rostrum	.0019	
		Corpus callosum: genu	.0018	
		Corpus callosum: isthmus	.0020	
		Cingulum left	.0016	
		Inferior occipito-frontal fascicle left	.0021	
		Inferior occipito-frontal fascicle right	.0016	
		Inferior longitudinal fascicle left	.0007	
		Inferior longitudinal fascicle right	.0005	
		Optic radiation left	.0015	
		Optic radiation right	.0018	
		Superior longitudinal fascicle I left	.0017	
		Superior longitudinal fascicle I right	.0020	
		Superior longitudinal fascicle II left	.0015	
		Superior longitudinal fascicle II right	.0019	
		Superior longitudinal fascicle III left	.0019	
		Superior thalamic radiation right	.0019	
		Uncinate fascicle left	<.0001	
		Thalamo-parietal left	.0017	
		Thalamo-parietal right	.0018	
		Thalamo-occipital left	.0018	
		Thalamo-occipital right	.0019	
		Striato-fronto-orbital left	.0019	
		Striato-fronto-orbital right	.0019	

Open Acce

Abbreviations: FA, fractional anisotropy; RD, radial diffusivity.

normal, and WM "atrophy" cannot be ascertained on visual inspection. While most FTD phenotypes are associated with the selective degeneration of specific WM tracts, these patterns are not visible on standard clinical sequences. It is also noteworthy that clinical pulse-sequences are typically optimized for speed of acquisition, often include slice gaps and operate with large voxel sizes, especially for FLAIR and T2w.

In a research setting, imaging traits are typically derived from contrasting a group of patients with a specific clinical profile or a specific mutation to a group of demographically matched controls. In bvFTD, progressive WM changes have been described in the uncinate fasciculus, cingulum and corpus callosum; and to a lesser extent in the anterior thalamic radiation, fornix and superior and inferior longitudinal fasciculus in both hemispheres (Agosta et al., 2012; Borroni et al., 2007; Lam et al., 2014; Mahoney et al., 2014; Whitwell et al., 2010). Studies in nvfPPA captured preferential left-sided changes in the anterior thalamic radiation, uncinate and superior longitudinal fasciculus (Agosta et al., 2012; Schwindt et al., 2013; Whitwell et al., 2010), which become more prominent in the right hemisphere over time (Lam et al., 2014). In svPPA, left-hemispheric uncinate, arcuate and inferior longitudinal fasciculus (Agosta et al., 2012; Borroni et al., 2007; Schwindt et al., 2013; Whitwell et al., 2010) degeneration has been consistently detected which remain relatively focal on longitudinal follow-up with some interval involvement of right frontotemporal regions (Agosta et al., 2012; Lam et al., 2014). In MAPT mutation carriers, early parahippocampal,

Brain and Behavior



FIGURF 2 Fractional anisotropy (FA) reductions at group level in patients with behavioral variant FTD (bvFTD), ALS-FTD patients without C9orf72 hexanucleotide expansions (ALSFTDC9-), ALS-FTD patients with C9orf72 hexanucleotide expansions (ALSFTDC9+), semantic variant primary progressive aphasia (svPPA) and nonfluent variant primary progressive aphasia (nfvPPA) compared to healthy controls at p < .01 controlling for age, sex and family-wise error

cingulate and uncus involvement can be detected (Jiskoot et al., 2018, 2019; Rohrer et al., 2010) accompanied by corpus callosum, inferior and superior longitudinal fasciculus and fornix degeneration (Jiskoot et al., 2018; Mahoney et al., 2014; Rohrer et al., 2010). In association with GRN, early corpus callosum and internal capsule changes have been described, followed by left-hemisphere predominant cingulum, inferior fronto-occipital, superior and inferior longitudinal fasciculus degeneration (Jiskoot et al., 2018, 2019; Rohrer et al., 2010). C9orf72 repeats have been linked to corticospinal tract, corpus callosum, thalamic radiation, cingulum, uncinate, superior and inferior longitudinal fasciculus degeneration (Jiskoot et al., 2018; Mahoney et al., 2014). The imaging signatures of rare genotypes-such as TARDBP and VCP-are



Increased radial diffusivity (RD) at group level in FIGURE 3 patients with behavioral variant FTD (bvFTD), ALS-FTD patients without C9orf72 hexanucleotide expansions (ALSFTDC9-), ALS-FTD patients with C9orf72 hexanucleotide expansions (ALSFTDC9+), semantic variant primary progressive aphasia (svPPA) and nonfluent variant primary progressive aphasia (nfvPPA) compared to healthy controls at p < .01 controlling for age, sex and family-wise error

poorly characterized as these have been predominantly evaluated in smaller case series (Häkkinen et al., 2020).

The group comparisons of academic imaging have relatively little to offer when the priority is the appraisal of cerebral pathology in individual patients; either in those with a suspected diagnosis or on follow-up of patients with an established diagnosis. While machine learning (ML) applications show promise in accurate patient categorization, they work best when ample training data are available which pertains to more common neurodegenerative conditions (Grollemund et al., 2020a, 2020b). An advantage of the presented method is that, contrary to ML applications, it does not impose a possible diagnostic label (category), but merely lists the tracts which are "affected" compared to normative controls. This leaves the interpretation of the

output text file to the clinicians to be judiciously integrated with clinical findings and the broader clinical context, family history, comorbid conditions, genetic susceptibility and so forth. As shown in Figure 1, the algorithm offers a list of affected tracts based on a single DWI scan which can be depicted visually if needed, but the main output is the text file with the relevant *z*-scores and *p*-values.

Another advantage of the approach is the detection of WM abnormalities in each hemisphere separately. The laterality of findings can then be interpreted in single subjects based on handedness which is particularly important in language variant FTDs. Our findings indicate left hemispheric dominant WM pathology in svPPA and nfvPA both at individual and group level. This is in striking contrast to the relatively symmetric WM degeneration observed in ALS-FTD. Academic studies using group comparisons typically pool data across right- and left-handed subjects which makes the interpretation of the laterality of findings more challenging. The quantitative evaluation of single subjects has other advantages. Pooled group-level data not only introduce undue heterogeneity in terms of handedness but also with regard to symptom duration and disease severity which undermines the value of group-level inferences and rendering them less pertinent to single participants. This study has exclusively focused on whiter matter alterations. The assessment of cortical gray matter changes has been previously tested in a similar framework (Tahedl, Chipika, et al., 2021; Tahedl, Li Hi Shing, et al., 2021). It is conceivable that additional imaging measures, such as basal ganglia volumes normalized for total intracranial volume (TIV), alternative WM metrics, metabolite ratios and network coherence indices could be interpreted in a similar framework with reference to normative data (Abidi et al., 2020, 2021; Dukic et al., 2019; Feron et al., 2018; Nasseroleslami et al., 2019; Proudfoot et al., 2018) as well as cord parameters in ALS-FTD cohorts (Bede et al., 2012; El Mendili et al., 2019; Lebouteux et al., 2014; Querin et al., 2019; Querin et al., 2018). Finally, it is plausible that statistical outputs from imaging modalities can be integrated into larger biomarker panels, which would include quantitative serum, cerebrospinal fluid, electroencephalographic, magnetoencephalographic, proteomic and neuropsychological indices (Blasco et al., 2018; Burke, Elamin, et al., 2016; Burke, Pinto-Grau, et al., 2016; Christidi et al., 2019; Devos et al., 2019; Dukic et al., 2019; Nasseroleslami et al., 2019; Proudfoot et al., 2018). While the group-level outputs of the z-scored-based strategy and TBSS are anatomically concordant, their sensitivity in detecting WM changes is different. It is noteworthy that FA on TBSS does not capture WM degeneration in svPPA and bvFTD even at p < .01 using the appropriate covariates. Using the tract-wise approach, FA reductions are readily detected in the anterior corpus callosum in bvFTD and in the left inferior occipito-frontal and left superior longitudinal fascicles in svFTD (Table 3). At an individual level, the z-score-based approach readily detects the degeneration of relevant WM tracts in these two groups, which may be "averaged out" by less severe cases in the group comparisons (Figure 1). TBSS generates voxelwise statistical maps projected on a WM skeleton which can be thresholded at a specific *p*-value, but it is typically reviewed visually, that is, anything below that threshold is highlighted as "affected" with a color spectrum map. In contrast, the text outputs from the z-score approach offer a list of "affected

tracts" which can be ranked in order of "severity" based on associated *p*-values.

Both the tractwise analyses and TBSS suggest that RD is more sensitive to detect WM alterations in FTD. Based on RD profiles, affected tracts in bvFTD include corpus callosum, corticospinal tract and a number of subcoritco-cortical projections such as the superior thalamic radiation, thalamo-premotor and striato-premotor fibers. The involvement of the corticospinal tract in bvFTD is of interest as another shared feature between ALS and FTD. The involvement of bundles linking subcortical and cortical regions supports previous findings (Chipika, Finegan, et al., 2020) and highlights the contribution of subcortical pathology to clinical manifestations (Christidi et al., 2018). WM degeneration in svPPA not only includes the corpus callosum, cingulum and arcuate degeneration but the left-hemisphere predominant involvement of long association fibers and projections from the thalamus and striatum (Table 3). The nfvPPA cohort exhibits widespread degeneration of both commissural and long association fibers with slight left hemispheric predominance in addition to thalamic and striatal projections. The C9orf72 negative ALS-FTD cohort not only exhibits widespread WM pathology in core ALS-associated regions such as the corticospinal tracts and corpus callosum, but in line with more recent studies, in the cerebellar peduncles, long association fibers, arcuate fasciculus, uncinate and cingulum (Bede, Chipika, et al., 2021; McKenna, Chipika, et al., 2021; Trojsi, Di Nardo, Caiazzo, et al., 2020) (Table 2). WM degeneration in ALS-FTD patients carrying the GGGGCC hexanucleotide expansion is comparable to the anatomical patterns observed in C9orf72-negative patients, but is more readily detected by FA reductions (Table 2). These observations highlight that contrary to previous suggestions, severe frontotemporal degeneration and subcortical involvement in ALS are not unique to the C9orf72 genotype.

In the absence of accompanying post mortem and CSF data, the participants of this study were merely categorized clinically. FTD phenotypes arise from different underlying proteinopathies (Chare et al., 2014; Josephs et al., 2011; Snowden et al., 2007); ALS-FTD is primarily linked to pTDP-43 (Geser et al., 2011), svPPA is nearly always associated with underlying TDP-43-C pathological aggregates (Bocchetta et al., 2020), nfvPPA is commonly associated with 4R tau (Spinelli et al., 2017) and molecular findings in bvFTD are thought to be heterogeneous (Perry et al., 2017). There are a number of study limitations we need to acknowledge, chief of which is the limited normative data at our disposal. Larger reference datasets stratified for narrow age brackets would permit more precise data interpretation. In this pilot study, we have only evaluated two diffusivity indices, but other diffusivity metrics, such as AD (Omer et al., 2017) or non-Gaussian diffusivity measures (Broad et al., 2019), could also be incorporated in zscore models. Finally, this is merely a cross-sectional study to test a quantitative, single-subject data interpretation framework. The natural expansion of this study would be tracking single subjects longitudinally to test whether our approach captures expanding WM pathology in single subjects over time. Notwithstanding these limitations, our findings indicate that our strategy offers valuable clinical insights in single-subjects and may be potentially developed into a viable clinical and pharmaceutical trial applications.

5 | CONCLUSIONS

Frontotemporal dementia is associated with subtype-specific WM signatures, and regional WM degeneration is a key contributor to phenotype-defining clinical manifestations. The early diagnosis of FTD soon after symptom onset is challenging, and the current clinical role of imaging is limited to the exclusion of alternative structural, inflammatory or neoplastic pathologies. As demonstrated, carefully designed computational pipelines enable the interpretation of individual diffusion datasets and the ascertainment of anatomical patterns of WM degeneration in vivo. The development, optimization and validation of similar imaging frameworks that categorize individual patients based on raw MR data should be a key research priority. These initiatives signal a departure from describing group-level signatures, and herald a paradigm shift to precision, individualized, computational radiology.

ACKNOWLEDGMENTS

We thank all participating patients and each healthy control for supporting this research study. Without their contribution this study would not have been possible. We also express our gratitude to the caregivers and family members of participating patients for facilitating attendance at our neuroimaging centre. We also thank all patients who had expressed interest in this research study, but could not participate due to medical or logistical reasons. Peter Bede and the Computational Neuroimaging Group are supported by the Health Research Board (HRB EIA-2017-019), the Spastic Paraplegia Foundation (SPF), the EU Joint Programme – Neurodegenerative Disease Research (JPND), the Andrew Lydon scholarship, the Irish Institute of Clinical Neuroscience (IICN), and the Iris O'Brien Foundation.

CONFLICT OF INTEREST

The authors declare no conflict interest.

AUTHOR CONTRIBUTIONS

Conceptualization of the study: Mary Clare McKenna, Marlene Tahedl and Peter Bede. Drafting of the manuscript: Mary Clare McKenna, Marlene Tahedl and Peter Bede. *Neuroimaging analyses*: Mary Clare McKenna, Marlene Tahedl, Aizuri Murad, Jasmin Lope and Peter Bede. *Revision of the manuscript for intellectual content*: Mary Clare McKenna, Marlene Tahedl, AM, JL, OH, SH and Peter Bede.

DATA AVAILABILITY STATEMENT

The data are not publicly available due to privacy or ethical restrictions.

ORCID

Peter Bede D https://orcid.org/0000-0003-0492-4772

REFERENCES

Abidi, M., Marco, G., Couillandre, A., Feron, M., Mseddi, E., Termoz, N., Querin, G., Pradat, P.-F., & Bede, P. (2020). Adaptive functional reorganization in amyotrophic lateral sclerosis: Coexisting degenerative and compensatory changes. *European Journal of Neurology*, 27(1), 121–128. https://doi.org/10.1111/ene.14042

- Abidi, M., Marco, G., Grami, F., Termoz, N., Couillandre, A., Querin, G., Bede, P., & Pradat, P.-F. (2021). Neural correlates of motor imagery of gait in amyotrophic lateral sclerosis. *Journal of Magnetic Resonance Imaging*, 53(1), 223–233. https://doi.org/10.1002/jmri.27335
- Agosta, F., Scola, E., Canu, E., Marcone, A., Magnani, G., Sarro, L., Copetti, M., Caso, F., Cerami, C., Comi, G., Cappa, S. F., Falini, A., & Filippi, M. (2012). White matter damage in frontotemporal lobar degeneration spectrum. *Cerebral Cortex*, 22(12), 2705–2714. https://doi.org/10.1093/ cercor/bhr288
- Aho-Özhan, H. E. A., Keller, J., Heimrath, J., Uttner, I., Kassubek, J., Birbaumer, N., Ludolph, A. C., & Lulé, D. (2016). Perception of emotional facial expressions in amyotrophic lateral sclerosis (ALS) at behavioural and brain metabolic level. *PLoS One*, 11(10), e0164655. https://doi.org/ 10.1371/journal.pone.0164655
- Bede, P., Bokde, A. L. W., Byrne, S., Elamin, M., Fagan, A. J., & Hardiman, O. (2012). Spinal cord markers in ALS: Diagnostic and biomarker considerations. *Amyotrophic Lateral Sclerosis*, 13(5), 407–415. https://doi.org/10. 3109/17482968.2011.649760
- Bede, P., Chipika, R. H., Christidi, F., Hengeveld, J. C., Karavasilis, E., Argyropoulos, G. D., Lope, J., Li Hi Shing, S., Velonakis, G., Dupuis, L., Doherty, M. A., Vajda, A., Mclaughlin, R. L., & Hardiman, O. (2021). Genotypeassociated cerebellar profiles in ALS: Focal cerebellar pathology and cerebro-cerebellar connectivity alterations. *Journal of Neurology, Neurosurgery, and Psychiatry*, 92, 1197–1205. https://doi.org/10.1136/jnnp-2021-326854
- Bede, P., Iyer, P. M., Finegan, E., Omer, T., & Hardiman, O. (2017). Virtual brain biopsies in amyotrophic lateral sclerosis: Diagnostic classification based on in vivo pathological patterns. *NeuroImage: Clinical*, 15, 653–658. https: //doi.org/10.1016/j.nicl.2017.06.010
- Bede, P., Murad, A., & Hardiman, O. (2021). Pathological neural networks and artificial neural networks in ALS: Diagnostic classification based on pathognomonic neuroimaging features. *Journal of Neurology*. https://doi. org/10.1007/s00415-021-10801-5
- Bede, P., Querin, G., & Pradat, P.-F. (2018). The changing landscape of motor neuron disease imaging: The transition from descriptive studies to precision clinical tools. *Current Opinion in Neurology*, 31(4), 431–438. https: //doi.org/10.1097/wco.00000000000569
- Blasco, H., Patin, F., Descat, A., Garçon, G., Corcia, P., Gelé, P., Lenglet, T., Bede, P., Meininger, V., Devos, D., Gossens, J. F., & Pradat, P.-F. (2018).
 A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. *PLoS One*, *13*(6), e0198116. https://doi.org/10.1371/journal.pone.0198116
- Bocchetta, M., Iglesias Espinosa, M. D. M., Lashley, T., Warren, J. D., & Rohrer, J. D. (2020). In vivo staging of frontotemporal lobar degeneration TDP-43 type C pathology. *Alzheimer's Research & Therapy*, 12(1), 34.
- Borroni, B., Brambati, S. M., Agosti, C., Gipponi, S., Bellelli, G., Gasparotti, R., Garibotto, V., Di Luca, M., Scifo, P., Perani, D., & Padovani, A. (2007). Evidence of white matter changes on diffusion tensor imaging in frontotemporal dementia. Archives of Neurology, 64(2), 246–251. https://doi.org/10. 1001/archneur.64.2.246
- Bouts, M. J. R. J., Möller, C., Hafkemeijer, A., Van Swieten, J. C., Dopper, E., Van Der Flier, W. M., Vrenken, H., Wink, A. M., Pijnenburg, Y. A. L., Scheltens, P., Barkhof, F., Schouten, T. M., De Vos, F., Feis, R. A., Van Der Grond, J., De Rooij, M., & Rombouts, S. A. R. B. (2018). Single subject classification of Alzheimer's disease and behavioral variant frontotemporal dementia using anatomical, diffusion tensor, and resting-state functional magnetic resonance imaging. *Journal of Alzheimer's Disease*, 62, 1827– 1839. https://doi.org/10.3233/JAD-170893
- Broad, R. J., Gabel, M. C., Dowell, N. G., Schwartzman, D. J., Seth, A. K., Zhang, H., Alexander, D. C., Cercignani, M., & Leigh, P. N. (2019). Neurite orientation and dispersion density imaging (NODDI) detects cortical and corticospinal tract degeneration in ALS. *Journal of Neurology, Neurosurgery, and Psychiatry*, 90(4), 404–411. https://doi.org/10.1136/jnnp-2018-318830
- Bron, E. E., Smits, M., Papma, J. M., Steketee, R. M. E., Meijboom, R., De Groot, M., Van Swieten, J. C., Niessen, W. J., & Klein, S. (2017). Multiparametric

computer-aided differential diagnosis of Alzheimer's disease and frontotemporal dementia using structural and advanced MRI. *European Radiology*, 27(8), 3372–3382. https://doi.org/10.1007/s00330-016-4691-x

- Burke, T., Elamin, M., Bede, P., Pinto-Grau, M., Lonergan, K., Hardiman, O., & Pender, N. (2016). Discordant performance on the 'Reading the Mind in the Eyes' Test, based on disease onset in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, 17, 467– 472. https://doi.org/10.1080/21678421.2016.1177088
- Burke, T., Pinto-Grau, M., Lonergan, K., Elamin, M., Bede, P., Costello, E., Hardiman, O., & Pender, N. (2016). Measurement of social cognition in amyotrophic lateral sclerosis: A population based study. *PLoS One*, 11(8), e0160850. https://doi.org/10.1371/journal.pone.0160850
- Cajanus, A., Hall, A., Koikkalainen, J., Solje, E., Tolonen, A., Urhemaa, T., Liu, Y., Haanpää, R. M., Hartikainen, P., Helisalmi, S., Korhonen, V., Rueckert, D., Hasselbalch, S., Waldemar, G., Mecocci, P., Vanninen, R., Van Gils, M., Soininen, H., Lötjönen, J., & Remes, A. M. (2018). Automatic MRI quantifying methods in behavioral-variant frontotemporal dementia diagnosis. Dementia and Geriatric Cognitive Disorders Extra, 8(1), 51–59. https: //doi.org/10.1159/000486849
- Canu, E., Agosta, F., Mandic-Stojmenovic, G., Stojković, T., Stefanova, E., Inuggi, A., Imperiale, F., Copetti, M., Kostic, V. S., & Filippi, M. (2017). Multiparametric MRI to distinguish early onset Alzheimer's disease and behavioural variant of frontotemporal dementia. *NeuroImage: Clinical*, 15, 428–438. https://doi.org/10.1016/j.nicl.2017.05.018
- Chagué, P., Marro, B., Fadili, S., Houot, M., Morin, A., Samper-González, J., Beunon, P., Arrivé, L., Dormont, D., Dubois, B., Teichmann, M., Epelbaum, S., & Colliot, O. (2020). Radiological classification of dementia from anatomical MRI assisted by machine learning-derived maps. *Journal of Neuroradiology Journal De Neuroradiologie*, 48, 412–418. https://doi. org/10.1016/j.neurad.2020.04.004
- Chare, L., Hodges, J. R., Leyton, C. E., Mcginley, C., Tan, R. H., Kril, J. J., & Halliday, G. M. (2014). New criteria for frontotemporal dementia syndromes: Clinical and pathological diagnostic implications. *Journal of Neurology, Neurosurgery, and Psychiatry*, 85(8), 865–870. https://doi.org/10. 1136/jnnp-2013-306948
- Chipika, R. H., Christidi, F., Finegan, E., Li Hi Shing, S., Mckenna, M. C., Chang, K. M., Karavasilis, E., Doherty, M. A., Hengeveld, J. C., Vajda, A., Pender, N., Hutchinson, S., Donaghy, C., Mclaughlin, R. L., Hardiman, O., & Bede, P. (2020). Amygdala pathology in amyotrophic lateral sclerosis and primary lateral sclerosis. *Journal of the Neurological Sciences*, 417, 117039. https: //doi.org/10.1016/j.jns.2020.117039
- Chipika, R. H., Finegan, E., Li Hi Shing, S., Hardiman, O., & Bede, P. (2019). Tracking a fast-moving disease: Longitudinal markers, monitoring, and clinical trial endpoints in ALS. Frontiers in Neurology, 10, 229. https://doi. org/10.3389/fneur.2019.00229
- Chipika, R. H., Finegan, E., Li Hi Shing, S., Mckenna, M. C., Christidi, F., Chang, K. M., Doherty, M. A., Hengeveld, J. C., Vajda, A., Pender, N., Hutchinson, S., Donaghy, C., Mclaughlin, R. L., Hardiman, O., & Bede, P. (2020). "Switchboard" malfunction in motor neuron diseases: Selective pathology of thalamic nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis. *NeuroImage: Clinical*, *27*, 102300. https://doi.org/10.1016/j.nicl.2020.102300
- Chipika, R. H., Siah, W. F., Mckenna, M. C., Li Hi Shing, S., Hardiman, O., & Bede, P. (2020). The presymptomatic phase of amyotrophic lateral sclerosis: Are we merely scratching the surface? *Journal of Neurology*, 268, 4607–4629. https://doi.org/10.1007/s00415-020-10289-5
- Christidi, F., Karavasilis, E., Rentzos, M., Kelekis, N., Evdokimidis, I., & Bede, P. (2018). Clinical and radiological markers of extra-motor deficits in amyotrophic lateral sclerosis. *Frontiers in Neurology*, *9*, 1005. https://doi.org/ 10.3389/fneur.2018.01005
- Christidi, F., Karavasilis, E., Rentzos, M., Velonakis, G., Zouvelou, V., Xirou, S., Argyropoulos, G., Papatriantafyllou, I., Pantolewn, V., Ferentinos, P., Kelekis, N., Seimenis, I., Evdokimidis, I., & Bede, P. (2019). Hippocampal pathology in amyotrophic lateral sclerosis: Selective vulnerability of sub-

fields and their associated projections. *Neurobiology of Aging*, 84, 178–188. https://doi.org/10.1016/j.neurobiolaging.2019.07.019

- Davatzikos, C., Resnick, S. M., Wu, X., Parmpi, P., & Clark, C. M. (2008). Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. *Neuroimage*, 41(4), 1220–1227. https://doi.org/10. 1016/j.neuroimage.2008.03.050
- Devos, D., Moreau, C., Kyheng, M., Garçon, G., Rolland, A. S., Blasco, H., Gelé, P., Timothée Lenglet, T., Veyrat-Durebex, C., Corcia, P., Dutheil, M., Bede, P., Jeromin, A., Oeckl, P., Otto, M., Meininger, V., Danel-Brunaud, V., Devedjian, J.-C., Duce, J. A., & Pradat, P. F. (2019). A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. *Science Reports*, 9(1), 2918. https://doi.org/10.1038/s41598-019-39739-5
- Donnelly-Kehoe, P. A., Pascariello, G. O., García, A. M., Hodges, J. R., Miller, B., Rosen, H., Manes, F., Landin-Romero, R., Matallana, D., Serrano, C., Herrera, E., Reyes, P., Santamaria-Garcia, H., Kumfor, F., Piguet, O., Ibanez, A., & Sedeño, L. (2019). Robust automated computational approach for classifying frontotemporal neurodegeneration: Multimodal/multicenter neuroimaging. *Alzheimers Dement (Amst)*, 11, 588– 598. https://doi.org/10.1016/j.dadm.2019.06.002
- Dukic, S., Mcmackin, R., Buxo, T., Fasano, A., Chipika, R., Pinto-Grau, M., Costello, E., Schuster, C., Hammond, M., Heverin, M., Coffey, A., Broderick, M., Iyer, P. M., Mohr, K., Gavin, B., Pender, N., Bede, P., Muthuraman, M., Lalor, E. C., Hardiman, O., & Nasseroleslami, B. (2019). Patterned functional network disruption in amyotrophic lateral sclerosis. *Human Brain Mapping*, 40(16), 4827–4842. https://doi.org/10.1002/hbm.24740
- Egger, K., Rau, A., Yang, S., Klöppel, S., Abdulkadir, A., Kellner, E., Frings, L., Hellwig, S., & Urbach, H. (2020). Automated voxel- and region-based analysis of gray matter and cerebrospinal fluid space in primary dementia disorders. *Brain Research*, 1739, 146800. https://doi.org/10.1016/j. brainres.2020.146800
- El Mendili, M. M., Querin, G., Bede, P., & Pradat, P.-F. (2019). Spinal cord imaging in amyotrophic lateral sclerosis: Historical concepts-novel techniques. Frontiers in Neurology, 10, 350. https://doi.org/10.3389/fneur. 2019.00350
- Feis, R. A., Bouts, M. J. R. J., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Schouten, T. M., De Vos, F., Van Der Grond, J., Van Swieten, J. C., & Rombouts, S. A. R. B. (2018). Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI. *NeuroImage: Clinical*, 20, 188–196. https://doi.org/10.1016/j.nicl. 2018.07.014
- Feis, R. A., Bouts, M. J. R. J., de Vos, F., Schouten, T. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., van der Grond, J., van Swieten, J. C., & Rombouts, S. A. R. B. (2019). A multimodal MRI-based classification signature emerges just prior to symptom onset in frontotemporal dementia mutation carriers. *Journal of Neurology, Neurosurgery & Psychiatry*, 90(11), 1207.
- Feis, R. A., Bouts, M. J. R. J., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Schouten, T. M., De Vos, F., Van Der Grond, J., Van Swieten, J. C., & Rombouts, S. A. R. B. (2019). Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI. *NeuroImage: Clinical*, 22, 101718. https://doi.org/10.1016/j.nicl. 2019.101718
- Feis, R. A., Van Der Grond, J., Bouts, M. J. R. J., Panman, J. L., Poos, J. M., Schouten, T. M., De Vos, F., Jiskoot, L. C., Dopper, E. G. P., Van Buchem, M. A., Van Swieten, J. C., & Rombouts, S. A. R. B. (2020). Classification using fractional anisotropy predicts conversion in genetic frontotemporal dementia, a proof of concept. *Brain Communications*, 2(2). https://doi. org/10.1093/braincomms/fcaa079
- Feron, M., Couillandre, A., Mseddi, E., Termoz, N., Abidi, M., Bardinet, E., Delgadillo, D., Lenglet, T., Querin, G., Welter, M.-L., Le Forestier, N., Salachas, F., Bruneteau, G., Del Mar Amador, M., Debs, R., Lacomblez, L., Meininger, V., Pélégrini-Issac, M., Bede, P., Pradat, P.-F., & De Marco, G. (2018). Extrapyramidal deficits in ALS: A combined biomechanical and neuroimaging study. *Journal of Neurology*, 265(9), 2125–2136. https: //doi.org/10.1007/s00415-018-8964-y

- Finegan, E., Li Hi Shing, S., Chipika, R. H., Doherty, M. A., Hengeveld, J. C., Vajda, A., Donaghy, C., Pender, N., Mclaughlin, R. L., Hardiman, O., & Bede, P. (2019). Widespread subcortical grey matter degeneration in primary lateral sclerosis: A multimodal imaging study with genetic profiling. *NeuroImage: Clinical*, 24, 102089. https://doi.org/10.1016/j.nicl. 2019.102089
- Finegan, E., Shing, S. L. H., Chipika, R. H., Chang, K. M., Mckenna, M. C., Doherty, M. A., Hengeveld, J. C., Vajda, A., Pender, N., Donaghy, C., Hutchinson, S., Mclaughlin, R. L., Hardiman, O., & Bede, P. (2021). Extramotor cerebral changes and manifestations in primary lateral sclerosis. *Brain Imaging and Behavior*, 15, 2283–2296, https://doi.org/10.1007/ s11682-020-00421-4
- Frings, L., Yew, B., Flanagan, E., Lam, B. Y. K., Hüll, M., Huppertz, H.-J., Hodges, J. R., & Hornberger, M. (2014). Longitudinal grey and white matter changes in frontotemporal dementia and Alzheimer's disease. *PLoS One*, 9(3), e90814. https://doi.org/10.1371/journal.pone.0090814
- Geser, F., Prvulovic, D., O'dwyer, L., Hardiman, O., Bede, P., Bokde, A. L. W., Trojanowski, J. Q., & Hampel, H. (2011). On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. *Progress in Neurobiology*, *95*(4), 649–662. https://doi.org/ 10.1016/j.pneurobio.2011.08.011
- Grollemund, V., Chat, G. L., Secchi-Buhour, M.-S., Delbot, F., Pradat-Peyre, J.-F., Bede, P., & Pradat, P.-F. (2020a). Development and validation of a 1year survival prognosis estimation model for Amyotrophic Lateral Sclerosis using manifold learning algorithm UMAP. *Science Reports*, 10(1), 13378. https://doi.org/10.1038/s41598-020-70125-8
- Grollemund, V., Chat, G. L., Secchi-Buhour, M.-S., Delbot, F., Pradat-Peyre, J.-F., Bede, P., & Pradat, P.-F. (2020b). Manifold learning for amyotrophic lateral sclerosis functional loss assessment: Development and validation of a prognosis model. *Journal of Neurology*, 268, 825–850. https://doi.org/ 10.1007/s00415-020-10181-2
- Grollemund, V., Pradat, P.-F., Querin, G., Delbot, F., Le Chat, G., Pradat-Peyre, J.-F., & Bede, P. (2019). Machine learning in amyotrophic lateral sclerosis: Achievements, pitfalls, and future directions. *Frontiers in Neuroscience*, 13, 135. https://doi.org/10.3389/fnins.2019.00135
- Häkkinen, S., Chu, S. A., & Lee, S. E. (2020). Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. *Neurobiology of Disease*, 145, 105063. https://doi.org/10.1016/j.nbd.2020.105063
- Hardiman, O., Doherty, C. P., Elamin, M., & Bede, P. (2016). Neurodegenerative disorders: A clinical guide. Springer Cham Heidelberg New York Dordrecht London© Springer International Publishing Switzerland 2016: Springer International Publishing.
- Hu, J., Qing, Z., Liu, R., Zhang, X., Lv, P., Wang, M., Wang, Y., He, K., Gao, Y., & Zhang, B. (2020). Deep learning-based classification and voxel-based visualization of frontotemporal dementia and Alzheimer's disease. *Frontiers in Neuroscience*, 14, 626154. https://doi.org/10.3389/fnins.2020. 626154
- Jiskoot, L. C., Bocchetta, M., Nicholas, J. M., Cash, D. M., Thomas, D., Modat, M., Ourselin, S., Rombouts, S. A. R. B., Dopper, E. G. P., Meeter, L. H., Panman, J. L., Minkelen, R., Ende, E. L., Donker Kaat, L., Pijnenburg, Y. A. L., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M. C., ... Warren, J. (2018). Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 5(9), 1025–1036. https://doi.org/10.1002/acn3.601
- Jiskoot, L. C., Panman, J. L., Meeter, L. H., Dopper, E. G. P., Donker Kaat, L., Franzen, S., Van Der Ende, E. L., Van Minkelen, R., Rombouts, S. A. R. B., Papma, J. M., & Van Swieten, J. C. (2019). Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. *Brain*, 142(1), 193–208. https://doi.org/10.1093/ brain/awy288
- Josephs, K. A., Hodges, J. R., Snowden, J. S., Mackenzie, I. R., Neumann, M., Mann, D. M., & Dickson, D. W. (2011). Neuropathological background of phenotypical variability in frontotemporal dementia. *Acta Neuropathologica*, 122(2), 137–153. https://doi.org/10.1007/s00401-011-0839-6

Kenna, K. P., Mclaughlin, R. L., Byrne, S., Elamin, M., Heverin, M., Kenny, E. M., Cormican, P., Morris, D. W., Donaghy, C. G., Bradley, D. G., & Hardiman, O. (2013). Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. *Journal of Medical Genetics*, 50(11), 776–783. https://doi.org/10.1136/jmedgenet-2013-101795

WII FY

- Kim, J. P., Kim, J., Park, Y. H., Park, S. B., Lee, J. S., Yoo, S., Kim, E.-J., Kim, H. J., Na, D. L., Brown, J. A., Lockhart, S. N., Seo, S. W., & Seong, J.-K. (2019). Machine learning based hierarchical classification of frontotemporal dementia and Alzheimer's disease. *NeuroImage: Clinical, 23*, 101811. https://doi.org/10.1016/j.nicl.2019.101811
- Klöppel, S., Peter, J., Ludl, A., Pilatus, A., Maier, S., Mader, I., Heimbach, B., Frings, L., Egger, K., Dukart, J., Schroeter, M. L., Perneczky, R., Häussermann, P., Vach, W., Urbach, H., Teipel, S., Hüll, M., Abdulkadir, A., ... for the Alzheimer's Disease Neuroimaging Initiative. (2015). Applying automated MR-based diagnostic methods to the memory clinic: A prospective study. *Journal of Alzheimer's Disease*, 47, 939–954. https://doi.org/10. 3233/JAD-150334
- Koikkalainen, J., Rhodius-Meester, H., Tolonen, A., Barkhof, F., Tijms, B., Lemstra, A. W., Tong, T., Guerrero, R., Schuh, A., Ledig, C., Rueckert, D., Soininen, H., Remes, A. M., Waldemar, G., Hasselbalch, S., Mecocci, P., van der Flier, W., & Lötjönen, J. (2016). Differential diagnosis of neurodegenerative diseases using structural MRI data. *NeuroImage: Clinical*, 11, 435– 449. https://doi.org/10.1016/j.nicl.2016.02.019
- Lam, B. Y. K., Halliday, G. M., Irish, M., Hodges, J. R., & Piguet, O. (2014). Longitudinal white matter changes in frontotemporal dementia subtypes. *Human Brain Mapping*, 35(7), 3547–3557. https://doi.org/10.1002/hbm. 22420
- Lebouteux, M.-V., Franques, J., Guillevin, R., Delmont, E., Lenglet, T., Bede, P., Desnuelle, C., Pouget, J., Pascal-Mousselard, H., Pradat, & P.-F. (2014). Revisiting the spectrum of lower motor neuron diseases with snake eyes appearance on magnetic resonance imaging. *European Journal of Neurology*, 21(9), 1233–1241. https://doi.org/10.1111/ene.12465
- Li Hi Shing, S., Lope, J., Chipika, R. H., Hardiman, O., & Bede, P. (2021). Extramotor manifestations in post-polio syndrome (PPS): Fatigue, cognitive symptoms and radiological features. *Neurol Sci*, 42, 4569–4581. https: //doi.org/10.1007/s10072-021-05130-4
- Li Hi Shing, S., Lope, J., Mckenna, M. C., Chipika, R. H., Hardiman, O., & Bede, P. (2021). Increased cerebral integrity metrics in poliomyelitis survivors: Putative adaptation to longstanding lower motor neuron degeneration. *Journal of the Neurological Sciences*, 424, 117361. https://doi.org/ 10.1016/j.jns.2021.117361
- Lule, D., Diekmann, V., Muller, H.-P., Kassubek, J., Ludolph, A. C., & Birbaumer, N. (2010). Neuroimaging of multimodal sensory stimulation in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*, 81(8), 899–906. https://doi.org/10.1136/jnnp.2009.192260
- Ma, D., Lu, D., Popuri, K., Wang, L., & Beg, M. F. (2020). Differential diagnosis of frontotemporal dementia, Alzheimer's disease, and normal aging using a multi-scale multi-type feature generative adversarial deep neural network on structural magnetic resonance images. *Frontiers in Neuroscience*, 14, 853. https://doi.org/10.3389/fnins.2020.00853
- Mahoney, C. J., Ridgway, G. R., Malone, I. B., Downey, L. E., Beck, J., Kinnunen, K. M., Schmitz, N., Golden, H. L., Rohrer, J. D., Schott, J. M., Rossor, M. N., Ourselin, S., Mead, S., Fox, N. C., & Warren, J. D. (2014). Profiles of white matter tract pathology in frontotemporal dementia. *Human Brain Mapping*, 35(8), 4163–4179. https://doi.org/10.1002/hbm.22468
- Manera, A. L., Dadar, M., Van Swieten, J. C., Borroni, B., Sanchez-Valle, R., Moreno, F., Laforce Jr, R., Graff, C., Synofzik, M., Galimberti, D., Rowe, J. B., Masellis, M., Tartaglia, M. C., Finger, E., Vandenberghe, R., De Mendonca, A., Tagliavini, F., Santana, I., Butler, C. R., ... Collins, D. L. (2021). MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. *Journal of Neurology, Neurosurgery, and Psychiatry*, 92, 608–616. https://doi.org/10.1136/jnnp-2020-324106
- Mckenna, M. C., Chipika, R. H., Li Hi Shing, S., Christidi, F., Lope, J., Doherty, M. A., Hengeveld, J. C., Vajda, A., Mclaughlin, R. L., Hardiman, O., Hutchinson, S., Bede, P. (2021). Infratentorial pathology in frontotemporal

dementia: Cerebellar grey and white matter alterations in FTD phenotypes. *Journal of Neurology*, *268*, 4687–4697. https://doi.org/10.1007/ s00415-021-10575-w

- Mckenna, M. C., Corcia, P., Couratier, P., Siah, W. F. Pradat, P.-F., & Bede, P. (2021). Frontotemporal pathology in motor neuron disease phenotypes: Insights from neuroimaging. *Frontiers in Neurology*, 12, 723450. https:// doi.org/10.3389/fneur.2021.723450
- Möller, C., Pijnenburg, Y. A. L., Van Der Flier, W. M., Versteeg, A., Tijms, B., De Munck, J. C., Hafkemeijer, A., Rombouts, S. A. R. B., Van Der Grond, J., Van Swieten, J., Dopper, E., Scheltens, P., Barkhof, F., Vrenken, H., & Wink, A. M. (2016). Alzheimer disease and behavioral variant frontotemporal dementia: Automatic classification based on cortical atrophy for singlesubject diagnosis. *Radiology*, 279(3), 838–848. https://doi.org/10.1148/ radiol.2015150220
- Nasseroleslami, B., Dukic, S., Broderick, M., Mohr, K., Schuster, C., Gavin, B., Mclaughlin, R., Heverin, M., Vajda, A., Iyer, P. M., Pender, N., Bede, P., Lalor, E. C., & Hardiman, O. (2019). Characteristic increases in EEG connectivity correlate with changes of structural MRI in amyotrophic lateral sclerosis. *Cerebral Cortex*, 29(1), 27–41. https://doi.org/10.1093/cercor/ bhx301
- Omer, T., Finegan, E., Hutchinson, S., Doherty, M., Vajda, A., Mclaughlin, R. L., Pender, N., Hardiman, O., & Bede, P. (2017). Neuroimaging patterns along the ALS-FTD spectrum: A multiparametric imaging study. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, 18(7–8), 611– 623. https://doi.org/10.1080/21678421.2017.1332077
- Perry, D. C., Brown, J. A., Possin, K. L., Datta, S., Trujillo, A., Radke, A., Karydas, A., Kornak, J., Sias, A. C., Rabinovici, G. D., Gorno-Tempini, M. L., Boxer, A. L., De May, M., Rankin, K. P., Sturm, V. E., Lee, S. E., Matthews, B. R., Kao, A. W., Vossel, K. A., ... Seeley, W. W. (2017). Clinicopathological correlations in behavioural variant frontotemporal dementia. *Brain:* A Journal of Neurology, 140(12), 3329–3345. https://doi.org/10.1093/ brain/awx254
- Pioro, E. P., Turner, M. R., & Bede, P. (2020). Neuroimaging in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21(sup1), 18–27. https://doi.org/10.1080/21678421.2020.1837176
- Proudfoot, M., Bede, P., & Turner, M. R. (2018). Imaging cerebral activity in amyotrophic lateral sclerosis. Frontiers in Neurology, 9, 1148. https://doi. org/10.3389/fneur.2018.01148
- Querin, G., Bede, P., El Mendili, M. M., Li, M., Pélégrini-Issac, M., Rinaldi, D., Catala, M., Saracino, D., Salachas, F., Camuzat, A., Marchand-Pauvert, V., Cohen-Adad, J., Colliot, O., Le Ber, I., & Pradat, P.-F. (2019). Presymptomatic spinal cord pathology in c9orf72 mutation carriers: A longitudinal neuroimaging study. *Annals of Neurology*, 86(2), 158–167. https: //doi.org/10.1002/ana.25520
- Querin, G., El Mendili, M.-M., Bede, P., Delphine, S., Lenglet, T., Marchand-Pauvert, V., & Pradat, P.-F. (2018). Multimodal spinal cord MRI offers accurate diagnostic classification in ALS. *Journal of Neurology, Neurosurgery, and Psychiatry*, 89(11), 1220–1221. https://doi.org/10.1136/ jnnp-2017-317214
- Raffelt, D., et al. (2017). Bias Field Correction and Intensity Normalisation for Quantitative Analysis of Apparent Fibre Density. Proc. ISMRM, 26, 3541
- Rohrer, J. D., Ridgway, G. R., Modat, M., Ourselin, S., Mead, S., Fox, N. C., Rossor, M. N., & Warren, J. D. (2010). Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. *Neuroimage*, 53(3), 1070–1076. https://doi.org/10.1016/ j.neuroimage.2009.12.088
- Schuster, C., Hardiman, O., & Bede, P. (2016). Development of an automated MRI-Based diagnostic protocol for amyotrophic lateral sclerosis using disease-specific pathognomonic features: A quantitative diseasestate classification study. *PLoS One*, 11(12), e0167331. https://doi.org/ 10.1371/journal.pone.0167331
- Schuster, C., Hardiman, O., & Bede, P. (2017). Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical character-

istics. BMC Neurology, 17(1), 73. https://doi.org/10.1186/s12883-017-0854-x

- Schwindt, G. C., Graham, N. L., Rochon, E., Tang-Wai, D. F., Lobaugh, N. J., Chow, T. W., & Black, S. E. (2013). Whole-brain white matter disruption in semantic and nonfluent variants of primary progressive aphasia. *Human Brain Mapping*, 34(4), 973–984. https://doi.org/10.1002/hbm.21484
- Snowden, J., Neary, D., & Mann, D. (2007). Frontotemporal lobar degeneration: Clinical and pathological relationships. Acta Neuropathologica, 114(1), 31–38. https://doi.org/10.1007/s00401-007-0236-
- Spinelli, E. G., Mandelli, M. L., Miller, Z. A., Santos-Santos, M. A., Wilson, S. M., Agosta, F., Grinberg, L. T., Huang, E. J., Trojanowski, J. Q., Meyer, M., Henry, M. L., Comi, G., Rabinovici, G., Rosen, H. J., Filippi, M., Miller, B. L., Seeley, W. W., & Gorno-Tempini, M. L. (2017). Typical and atypical pathology in primary progressive aphasia variants. *Annals of Neurology*, 81(3), 430–443. https://doi.org/10.1002/ana.24885
- Tahedl, M., Chipika, R. H., Lope, J., Li Hi Shing, S., Hardiman, O., Bede, P. (2021). Cortical progression patterns in individual ALS patients across multiple timepoints: A mosaic-based approach for clinical use. *Journal* of Neurology, 268, 1913–1926. https://doi.org/10.1007/s00415-020-10368-7
- Tahedl, M., Li Hi Shing, S., Finegan, E., Chipika, R. H., Lope, J., Hardiman, O., & Bede, P. (2021). Propagation patterns in motor neuron diseases: Individual and phenotype-associated disease-burden trajectories across the UMN-LMN spectrum of MNDs. *Neurobiology of Aging*, 109, 78–87. https://doi.org/10.1016/j.neurobiolaging.2021.04.031
- Tong, T., Ledig, C., Guerrero, R., Schuh, A., Koikkalainen, J., Tolonen, A., Rhodius, H., Barkhof, F., Tijms, B., Lemstra, A. W., Soininen, H., Remes, A. M., Waldemar, G., Hasselbalch, S., Mecocci, P., Baroni, M., Lötjönen, J., Flier, W. V. D., & Rueckert, D. (2017). Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. *NeuroImage: Clinical*, 15, 613–624. https://doi.org/10.1016/j.nicl.2017. 06.012
- Torso, M., Bozzali, M., Cercignani, M., Jenkinson, M., & Chance, S. A. (2020). Using diffusion tensor imaging to detect cortical changes in frontotemporal dementia subtypes. *Scientific Reports*, 10(1), 11237-11237. https://doi.org/10.1038/s41598-020-68118-8
- Trojsi, F., Di Nardo, F., Caiazzo, G., Siciliano, M., D'alvano, G., Ferrantino, T., Passaniti, C., Ricciardi, D., Esposito, S., Lavorgna, L., Russo, A., Bonavita, S., Cirillo, M., Santangelo, G., Esposito, F., & Tedeschi, G. (2020). Hippocampal connectivity in Amyotrophic Lateral Sclerosis (ALS): More than Papez circuit impairment. *Brain Imaging Behav*, 15, 2126–2138. https://doi.org/ 10.1007/s11682-020-00408-1
- Trojsi, F., Di Nardo, F., Siciliano, M., Caiazzo, G., Femiano, C., Passaniti, C., Ricciardi, D., Russo, A., Bisecco, A., Esposito, S., Monsurrò, M. R., Cirillo, M., Santangelo, G., Esposito, F., & Tedeschi, G. (2020). Frontotemporal degeneration in amyotrophic lateral sclerosis (ALS): A longitudinal MRI one-year study. CNS Spectrums, 26, 258–267. https://doi.org/10.1017/ s109285292000005x
- Trojsi, F., Esposito, F., De Stefano, M., Buonanno, D., Conforti, F. L., Corbo, D., Piccirillo, G., Cirillo, M., Monsurrò, M. R., Montella, P., & Tedeschi, G. (2015). Functional overlap and divergence between ALS and bvFTD. *Neurobiology of Aging*, 36(1), 413–423. https://doi.org/10.1016/j. neurobiolaging.2014.06.025
- Trojsi, F., Siciliano, M., Femiano, C., Santangelo, G., Lunetta, C., Calvo, A., Moglia, C., Marinou, K., Ticozzi, N., Ferro, C., Scialò, C., Sorarù, G., Conte, A., Falzone, Y. M., Tortelli, R., Russo, M., Sansone, V. A., Chiò, A., Mora, G., ... Mandrioli, J. (2019). Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Frontiers in Neuroscience, 13, 485. https://doi.org/10.3389/fnins.2019.00485
- Vernooij, M. W., Jasperse, B., Steketee, R., Koek, M., Vrooman, H., Ikram, M. A, Papma, J., Van Der Lugt, A., Smits, M., & Niessen, W. J. (2018). Automatic normative quantification of brain tissue volume to support the diagnosis of dementia: A clinical evaluation of diagnostic accuracy.

NeuroImage: Clinical, 20, 374-379. https://doi.org/10.1016/j.nicl.2018. 08.004

- Verstraete, E., Turner, M. R., Grosskreutz, J., Filippi, M., & Benatar, M. (2015). Mind the gap: The mismatch between clinical and imaging metrics in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 16(7– 8), 524–529. https://doi.org/10.3109/21678421.2015.1051989
- Wang, J., Redmond, S. J., Bertoux, M., Hodges, J. R., & Hornberger, M. (2016). A comparison of magnetic resonance imaging and neuropsychological examination in the diagnostic distinction of Alzheimer's disease and behavioral variant frontotemporal dementia. *Frontiers* in Aging Neuroscience, 8, 119–119. https://doi.org/10.3389/fnagi.2016 .00119
- Wen, J., Zhang, H., Alexander, D. C., Durrleman, S., Routier, A., Rinaldi, D., Houot, M., Couratier, P., Hannequin, D., Pasquier, F., Zhang, J., Colliot, O., Le Ber, I., & Bertrand, A. (2019). Neurite density is reduced in the presymptomatic phase of C9orf72 disease. *Journal of Neurology, Neurosurgery, and Psychiatry*, 90(4), 387–394. https://doi.org/10.1136/jnnp-2018-318994
- Whitwell, J. L., Avula, R., Senjem, M. L., Kantarci, K., Weigand, S. D., Samikoglu, A., Edmonson, H. A., Vemuri, P., Knopman, D. S., Boeve, B. F., Petersen, R. C., Josephs, K. A., & Jack, C. R. (2010). Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia. *Neurology*, 74(16), 1279–1287. https://doi.org/10.1212/WNL. 0b013e3181d9edde

Young, A. L., Marinescu, R. V., Oxtoby, N. P., Bocchetta, M., Yong, K., Firth, N. C., Cash, D. M., Thomas, D. L., Dick, K. M., Cardoso, J., Van Swieten, J., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M. C., Rowe, J. B., Graff, C., Tagliavini, F., Frisoni, ... Alexander, D. C. (2018). Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nature Communication*, 9(1), 4273. https://doi.org/10.1038/s41467-018-05892-0

Μπ έγ

Yu, Q., Mai, Y., Ruan, Y., Luo, Y., Zhao, L., Fang, W., Cao, Z., Li, Y., Liao, W., Xiao, S., Mok, V. C. T., Shi, L., Liu, J., National Alzheimer's Coordinating Center, the Alzheimer's Disease Neuroimaging Initiative, & Frontotemporal Lobar Degeneration Neuroimaging Initiative. (2021). An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer's disease. *Alzheimer's Research & Therapy*, 13(1), 2.

How to cite this article: McKenna, M. C., Tahedl, M., Murad, A., Lope, J., Hardiman, O., Hutchinson, S., & Bede, P. (2022). White matter microstructure alterations in frontotemporal dementia: Phenotype-associated signatures and single-subject interpretation. *Brain and Behavior*, 12, e2500. https://doi.org/10.1002/brb3.2500